Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (January 2023)
34 slides from Immunome's investor presentation, Jan 6, 2023
Slide 1: Harnessing the Power of the Human Memory B Cell
Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 2: Disclaimers and Forward-Looking Statements
2 Disclaimers and Forward - Looking Statements Copyright © 2023 Immunome, Inc. All rights reserved. This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Ref
Slide 3: Immunome "At a Glance"
Immunome “At a Glance” Disruptive Technology Leveraging Human Immune Response 3 Copyright © 2023 Immunome, Inc. All rights reserved. → Interrogates memory B cells, the most educated component of the human immune system → Potential across multiple therapeutic areas Patient Informed Drug Discovery Eng
Slide 4: Strategic Discovery Collaboration with AbbVie
Strategic Discovery Collaboration with AbbVie AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets 4 Copyright © 2023 Immunome, Inc. All rights reserved. → Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target - antib
Slide 5: B cells: Critical Players in Immunity Oncology
B cells: Critical Players in Immunity Oncology 5 Copyright © 2023 Immunome, Inc. All rights reserved. → B cell infiltration more closely associated with survival than T cell presence in multiple cancers → Success of I/O therapies appears to be associated with coordinated response including B cells a
Slide 6: Cataloging the Context-Dependent B-cell Response Against Cancer
Cataloging the Context - Dependent B - cell Response Against Cancer 6 Copyright © 2023 Immunome, Inc. All rights reserved. → Cancer cells modify their microenvironment to make it fertile ground for tumor growth → The human immune system makes a coordinated, time - dependent, attack against cancer in
Slide 7: We See the Disease Through the Lens of a Memory B-cell
We See the Disease Through the Lens of a Memory B - cell Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale 7 Copyright © 2023 Immunome, Inc. All rights reserved. Antibody Screening Proprietary, multiplexed interrogation of patient B cell responses agai
Slide 8: Broad Applicability Across Therapeutic Areas
Broad Applicability Across Therapeutic Areas Unbiased Interrogation Unveils Targets & Underexplored Biology: Examples 8 Copyright © 2023 Immunome, Inc. All rights reserved. Immunology: Conserved Epitopes Identification of antibodies specific for broadly conserved epitopes, including across species I
Slide 9: Platform has Potential for Diversified Partnering Strategy Across Therapeutic Areas
9 Platform has Potential for Diversified Partnering Strategy Across Therapeutic Areas Copyright © 2023 Immunome, Inc. All rights reserved. → $30M Upfront → $70M Platform Milestones → $120M/target Development and First Commercial Sale Milestones → Sales - based Milestones → Tiered Royalties on Global
Slide 10: Immunome Pipeline
Immunome Pipeline Targets Identified from Authentic Human Immune Response 10 Copyright © 2023 Immunome, Inc. All rights reserved. PROGRAM POTENTIAL DISEASE OF RELEVANCE STAGE NEXT MILESTONE IMM - BCP - 01 (Anti SARS - CoV - 2)* Three antibody cocktail (multi - modal action, including neutralization
Slide 11: Oncology
Oncology Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 12: Immunome's Discovery Engine
Immunome’s Discovery Engine Functional B - cell Interrogation to Actionable Public Targets 12 Copyright © 2023 Immunome, Inc. All rights reserved. Functional screening prioritizes patient - derived antibodies that bind to actionable public targets 03 Memory B Cells Represent One of the Most Educated
Slide 13: Unveiling "Tumor Context"
Unveiling “Tumor Context” Novel Insights into Tumor Targets and Biological Processes 13 Copyright © 2023 Immunome, Inc. All rights reserved. Human immune system sees unique features of cancer cells → Mutations, Unexpected localization of proteins (ectopic expression) on tumor surface → Splice varian
Slide 14: Discovery Engine Highlights Ectopically Expressed Targets
Discovery Engine Highlights Ectopically Expressed Targets A Novel Class of Targets with Potentially High Tumor Selectivity 14 Copyright © 2023 Immunome, Inc. All rights reserved. → Some proteins normally found intracellularly appear to be selectively located on the extracellular side of plasma membr
Slide 15: Example of an Ectopically Expressed Target as an ADC
Example of an Ectopically Expressed Target as an ADC 15 Copyright © 2023 Immunome, Inc. All rights reserved. *Immunome internal data 0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0 0 10 20 30 40 Raw Binding Signal S - S c o r e 17. PR121-00372 C11orf68 Target B Ab Highly Selective for Single Protein Target Select
Slide 16: IMM-ONC-01 Anti IL-38 Antibody
IMM - ONC - 01 Anti IL - 38 Antibody Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 17: Anti IL-38 Antibody Therapy has Potential to Be an Important Advancement in Cancer Care
IND filing anticipated mid 2023 IMM - ONC - 01 Anti IL - 38 Antibody Anti IL - 38 Antibody Therapy has Potential to Be an Important Advancement in Cancer Care 17 Copyright © 2023 Immunome, Inc. All rights reserved. Blocking IL - 38 leads to tumor control in preclinical in vivo testing in two differe
Slide 18: Growing Evidence of IL-38 as a Key Immune Modulator
Growing Evidence of IL - 38 as a Key Immune Modulator 18 Copyright © 2023 Immunome, Inc. All rights reserved. Takeda et al. PLoS One (2017)
Slide 19: IL-38 is Expressed in Multiple Tumors
IL - 38 is Expressed in Multiple Tumors 2 IL - 38 Protein Expression In HNSCC Aligns With Transcriptional Data 3 → Tumor versus Healthy Adjacent Tissue Expression (% of Patient Expression) → Pathology Scoring of Individual Patient Samples by Stage IL - 38 Expression in Solid Tumors 19 Copyright © 20
Slide 20: IL-38 Overexpression Inhibits Infiltration of T cells into Tumors
IL - 38 Overexpression Inhibits Infiltration of T cells into Tumors In Vivo High IL - 38 Expression is Associated with Reduced Immune Cell Infiltration* → IL - 38 high tumor samples correlate with reduced infiltration of multiple immune subsets, especially in lung, head & neck, and gastroesophageal
Slide 21: Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models
IMM - ONC - 01 Anti IL - 38 Antibody Blocking IL - 38 Leads to Tumor Control in Two Different Tumor Models 1 21 Copyright © 2023 Immunome, Inc. All rights reserved. Demonstration of Anti - Tumor Activity (B16F10 Model) Induction of Anti - Tumor Memory (EMT6 Model) → Immunologically cold tumor model
Slide 22: IL-38 and Potential Combinations
IL - 38 and Potential Combinations Mechanistic Rationales for Both Chemotherapy and Immune Checkpoint Combinations 22 Copyright © 2023 Immunome, Inc. All rights reserved. Tumor Cells Can Secrete IL - 38 Upon Apoptosis Induction IL - 38 Levels Correlate with PD - L1 Expression → IL - 38 secretion ass
Slide 23: IMM-ONC-01 Program Summary
23 IMM - ONC - 01 Program Summary Copyright © 2023 Immunome, Inc. All rights reserved. → In vitro and in vivo preclinical research confirms antitumor activity of ONC - 01 in solid tumors as a monotherapy → Gene expression profiling of patient tumors suggest normal IL - 38 biology is co - opted by tu
Slide 24: Oncology Platform and Research Pipeline
ONCOLOGY Platform and Research Pipeline Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 25: Untapped Biology and Novel Therapeutic Targets
25 Untapped Biology and Novel Therapeutic Targets Copyright © 2023 Immunome, Inc. All rights reserved. TROP2 EGFR CD20 CD19 HER2 Novel targets have the potential to lead to more effective antibody - based therapies (including ADC, TCE & CAR - T modalities) Current Therapies are Based on Limited Know
Slide 26: IMM20059 Anti-EPN1 Antibody Targeting Ectopically Expressed Protein
Preclinical efficacy testing Impact of targeting ectopic EPN1: Mechanism of Action and anti - tumor effect EPN1 ectopically expressed on surface of cancer cells and exosomes in preclinical testing EPN1, a novel cancer target, identified by H&N cancer patient antibody response → Preliminary Immunome
Slide 27: Anti-EPN1 Antibody in Combination with PD-L1 Enhances Anti-Tumor Efficacy
Tumor Growth Anti - tumor Immune Response → Combination of IMM20059 + atezolizumab leads to significant tumor control in the B16.F10 model as compared to either therapy alone → IMM20059 + atezolizumab treatment of B16.F10 tumor - bearing mice leads to upregulation of intra - tumoral inflammatory che
Slide 28: Immunome Discovery Engine 2.0: Context Dependent Drug Discovery
Correlations lead to identification of actionable public targets Immunome Discovery Engine 2.0: Context Dependent Drug Discovery Beyond Memory B - cells: What Other Immune Components Play a Role in Response? 28 Copyright © 2023 Immunome, Inc. All rights reserved. Leverage big data sets and complex a
Slide 29: Financial Overview and Intellectual Property Snapshot
29 Financial Overview and Intellectual Property Snapshot Copyright © 2023 Immunome, Inc. All rights reserved. → Cash at least through 3Q 2024 → Capital efficient business model – partnerships and proprietary programs → Eligible for additional platform access payments during the research term in the
Slide 30: Immunome "At a Glance"
Immunome “At a Glance” Disruptive Technology Leveraging Human Immune Response 30 Copyright © 2023 Immunome, Inc. All rights reserved. → Interrogates memory B cells, the most educated component of the human immune system → Potential across multiple therapeutic areas Patient Informed Drug Discovery En
Slide 31: Collaboration with U.S. DoD & DHA for IMM-BCP-01 Program
IMM - BCP - 01 Copyright © 2023 Immunome, Inc. All rights reserved. Collaboration with U.S. DoD & DHA for IMM - BCP - 01 Program, Awarded Up to $17.6M in Funding* Phase 1b Topline Results * OTA: W911QY - 20 - 9 - 0019
Slide 32: IMM-BCP-01: Three Antibody Cocktail for the Treatment of COVID-19
PHASE 1B Identified Antibodies from SARS - CoV - 2 patient memory B cell response IMM - BCP - 01 three antibody cocktail designed to retain efficacy against emerging variants In vitro preclinical neutralization of variants that have emerged over time 1 In vitro neutralization translates into i n viv
Slide 33: IMM-BCP-01 Clinical Study Top Line Results: Safety and Pharmacokinetics
33 IMM - BCP01 - 001 Clinical Study Top Line Results: Safety and Pharmacokinetics Copyright © 2023 Immunome, Inc. All rights reserved. → Phase 1b, 2:1 randomization (n = 9; 6 active: 3 placebo) → Single dose of cocktail (600 mg total) administered as an intravenous infusion → No significant treatmen
Slide 34: IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms
34 IMM - BCP - 01 Neutralizes Virus Utilizing Different Mechanisms Copyright © 2023 Immunome, Inc. All rights reserved. Pre - fusion spike (S1 + S2) Post - fusion spike (S2) DIRECT ACE2 BLOCKADE ANTIBODY INDUCED CONFORMATIONAL CHANGE DESTABILIZES SPIKE PROTEIN* ACE2 1 2 IMM20253 IMM20190 + IMM20184